10-Q: Elevance Health Q2 2026 Earnings Decline Amidst Rising Costs

Elevance Health reports a 16.1% decrease in net income for Q2 2026 compared to the prior year, driven by increased medical costs and strategic investments, despite a slight rise in total operating revenue.

Summary

• Elevance Health reported a net income of $1.463 billion for the three months ended June 30, 2026, a decrease of 16.1% from $1.743 billion in the same period of 2025.
• For the six months ended June 30, 2026, net income was $3.227 billion, down 17.8% from $3.928 billion in the prior year.
• Total operating revenue for the second quarter of 2026 was $49.826 billion, an increase of 0.8% from $49.421 billion in Q2 2025.
• For the first six months of 2026, total operating revenue was $99.320 billion, up 1.2% from $98.186 billion in the comparable period of 2025.
• Diluted earnings per share (EPS) decreased to $6.71 in Q2 2026 from $7.72 in Q2 2025, and for the six-month period, EPS fell to $14.73 from $17.33.
• The company experienced a 1.5% decline in total medical membership from June 30, 2025, to June 30, 2026, largely due to Medicaid redeterminations and decreases in Medicare Advantage and Employer Group Risk-Based businesses.
• A significant factor impacting the six-month results was a loss contingency accrual of approximately $935 million related to Medicare Advantage risk adjustment data resubmission.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to significant declines in net income and EPS, coupled with membership attrition and rising benefit expenses, despite some revenue growth.

Positives

• Total operating revenue increased by 0.8% to $49.826 billion for the three months ended June 30, 2026, and by 1.2% to $99.320 billion for the six months ended June 30, 2026.
• Net investment income increased by 44.9% to $704 million for the three months ended June 30, 2026, and by 36.5% to $1.469 billion for the six months ended June 30, 2026.
• CarelonRx operating revenue increased by 5.7% for the three months and 5.3% for the six months, driven by higher average revenue per prescription and improved specialty pharmacy profitability.
• Carelon Services operating revenue increased by 7.2% for the three months and 9.8% for the six months, due to expansion in risk-based capabilities and behavioral health services.
• Vision membership saw a significant increase of 10.6%.

Negatives

• Shareholders net income decreased by 16.1% to $1.463 billion for the three months ended June 30, 2026, and by 17.8% to $3.227 billion for the six months ended June 30, 2026.
• Diluted EPS decreased by 13.1% to $6.71 for the three months and by 15.0% to $14.73 for the six months.
• Total medical membership declined by 1.5% to 44.9 million as of June 30, 2026.
• Benefit expense increased by 0.9% to $37.024 billion for the three months and by 0.9% to $72.639 billion for the six months, driven by higher medical costs.
• Operating expense increased by 11.0% for the three months and 15.3% for the six months, impacted by investments, regulatory matters, and a loss contingency accrual.
• The benefit expense ratio increased due to elevated medical cost trends in Medicaid and Medicare businesses.
• The operating expense ratio increased due to investments, regulatory matters, and the loss contingency accrual.

Risks

• Trends in healthcare costs and utilization rates could adversely affect financial performance.
• Reduced enrollment in key business segments like Medicaid and Medicare Advantage poses a risk.
• Changes in federal, state, and international laws and regulations impacting healthcare and insurance could have an adverse effect.
• Cyber-attacks or data security incidents could lead to significant liabilities and reputational damage.
• Failure to effectively maintain and modernize information systems, including AI, could impact operations.
• Negative changes in economic and market conditions could affect liquidity and investment portfolios.
• Intense competition and the inability to adapt to industry changes could hinder strategic growth.
• Risks associated with Medicare and Medicaid programs, including non-compliance and changes in ratings, could impact revenue and operations.

Future Outlook

The company expects the Public Exchange to be influenced by policy and regulatory changes. The expiration of enhanced Advance Premium Tax Credits (APTCs) on December 31, 2025, is expected to increase Public Exchange coverage premiums for affected individuals. The company anticipates ongoing regulatory guidance on Medicare and potential changes to risk adjustment programs.

Management Comments

• Elevance Health is a health company with the purpose of improving the health of humanity.
• We are working on program improvements in partnership with the states, strengthening care and provider network management, optimizing our clinical strategy to improve effectiveness and enhancing payment integrity to manage costs.
• We strive to price our health benefit products consistent with anticipated underlying medical cost trends.
• We believe that cash on hand, future operating cash receipts, investments and funds available under our commercial paper program, our 5-Year Facility and borrowings available from the FHLBs will be adequate to fund our expected cash disbursements over the next twelve months.

Industry Context

StockSavvy.ai notes that Elevance Health's Q2 2026 results reflect broader industry pressures, including rising medical costs and shifts in membership, particularly from Medicaid. The company's strategic investments in technology and workforce, alongside regulatory changes, are key factors influencing performance in the competitive health insurance landscape.

Comparison to Industry Standards

• Elevance Health's benefit expense ratio of 89.7% for Q2 2026 is higher than the industry average for health insurers, which typically ranges from 80% to 85%, indicating higher claim costs relative to premiums.
• The company's operating expense ratio of 11.1% for Q2 2026 is slightly above the typical industry benchmark of 10-11%, potentially due to strategic investments and regulatory compliance costs.
• The decline in total medical membership by 1.5% is a concern, as industry growth is often driven by expanding coverage, particularly in government programs like Medicare and Medicaid, where Elevance saw declines.
• The increase in net investment income, driven by alternative investments, aligns with a trend seen across the financial services sector seeking diversified returns in a fluctuating market.

Legal Proceedings

• Elevance Health is a defendant in multiple lawsuits consolidated into the In re Blue Cross Blue Shield Antitrust Litigation, alleging violations of antitrust laws. Settlement agreements have been reached with subscriber and provider plaintiffs, but follow-on cases from opt-out entities remain pending.
• The company is involved in Medicare Risk Adjustment Litigation initiated by the U.S. Department of Justice, alleging false certifications of diagnosis data submitted to CMS. Discovery is ongoing.
• CMS issued a notice regarding Medicare Advantage risk adjustment data submission requirements. The company completed required steps to avoid sanctions, and the enforcement process is closed. An accrual of $593 million remains for potential loss contingency.

Related Party Transactions

• Care delivery and enablement services provided to Mosaic Health (equity method investment) amounted to $193 million and $386 million for the three and six months ended June 30, 2026, respectively.
• Administrative services provided to Liberty Dental (equity method investment) for Medicare Advantage members amounted to $123 million and $256 million for the three and six months ended June 30, 2026, respectively.

Stakeholder Impact

• Shareholders may experience reduced returns due to the decrease in net income and EPS.
• Members may face impacts from rising medical costs and potential changes in coverage due to regulatory shifts.
• Employees may be affected by the ongoing 'Operating Model Transformation Program' which includes targeted workforce reductions and role realignments.
• Providers may be impacted by evolving payment models and regulatory changes within the healthcare system.

Next Steps

• Continue to manage medical cost trends through care management, program integrity, and specialty pharmacy management.
• Implement program improvements in partnership with states for Medicaid, strengthen care and provider network management, and optimize clinical strategy.
• Continue to monitor and adapt to policy and regulatory changes impacting the Public Exchange and Medicare/Medicaid programs.
• Modernize information technology platforms and streamline organizational structures as part of the 2026-2027 Operating Model Transformation Program.

Key Dates

Recommendation

While revenue shows modest growth and investment income improved, the significant decline in net income and EPS, coupled with membership attrition and rising medical costs, warrants a cautious approach. The company's strategic investments and ongoing transformation efforts may yield future benefits, but current headwinds suggest holding the stock until clearer signs of recovery emerge.

Keywords

Elevance Health, Form 10-Q, Quarterly Report, Health Insurance, Medical Costs, Membership, Financial Results, Healthcare Services